Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.83Last Year’s EPS
0.64Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 23, 2025
|% Change Since: 6.65%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
Penumbra, Inc. demonstrated strong financial performance with significant growth in the U.S. thrombectomy business and an improvement in gross margins. However, challenges in international markets, particularly in China, and flat gross margin expectations for Q2 present some concerns.Company Guidance
During Penumbra, Inc.'s first quarter 2025 conference call, the company reported a total revenue of $324.1 million, reflecting a 16.3% year-over-year growth on a reported basis and 16.9% on a constant currency basis. The U.S. thrombectomy revenue grew by 25% to $187.9 million, with a notable 42% increase in the USVTE franchise. The gross margin expanded to 66.6%, an improvement of 160 basis points from the previous year, while operating income rose to $40.4 million, representing 12.4% of revenue, a 550 basis point increase. The company anticipates achieving a gross margin profile of over 70% by the end of 2026. Penumbra maintained its total revenue growth guidance for 2025 at 12% to 14% year-over-year, despite removing $5 million in expected revenue from China due to macroeconomic conditions.Strong Revenue Growth
Penumbra, Inc. reported total revenue of $324.1 million, a year-over-year growth of 16.3% on a reported basis and 16.9% on a constant currency basis.
U.S. Thrombectomy Business Performance
U.S. Thrombectomy revenue increased by 25% year-over-year to $187.9 million, with the US VTE franchise leading with 42% year-over-year growth.
Gross Margin Improvement
The gross margin expanded to 66.6%, a 160 basis point increase over the prior year period.
Introduction of New Products
FDA clearance of Ruby XL, a new larger size diagnostic catheter-compatible peripheral coil, was received earlier than expected, with plans for a market launch in late Q2 or early Q3.
Positive Cash Flow and No Debt
The company ended the first quarter with cash and marketable securities balance of $378.8 million and no debt, reflecting strong operating profitability.
Raised Guidance for U.S. Thrombectomy Growth
The guidance for the U.S. Thrombectomy business was raised to a growth range of 20% to 21% year-over-year.
---
PEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 23, 2025 | $278.77 | $298.25 | +6.99% |
| Feb 18, 2025 | $271.14 | $303.76 | +12.03% |
| Oct 30, 2024 | $211.29 | $228.87 | +8.32% |
| Jul 30, 2024 | $173.09 | $167.09 | -3.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Penumbra (PEN) report earnings?
Penumbra (PEN) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Penumbra (PEN) earnings time?
Penumbra (PEN) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PEN EPS forecast?
PEN EPS forecast for the fiscal quarter 2025 (Q2) is 0.83.
---